The present invention relates to a method of making biopolymer including but not limited to bio plastic from animal by-products, more specifically from poultry feathers wherein the method of making a biopolymer comprises the steps: i) i) pre-treatment of native feathers; ii) extraction of keratin protein from pre-treated feathers in the presence of reducing agent; iii) polymerization by blending keratin protein with one or more plasticizer, one or more additive and one or more cross-linking agent, optionally in presence of at least one alkali hydroxide to obtain a polymer compound using one or more thermal processing techniques at a temperature in the range of 60° C. to 150° C.; and iv) applying pressure and subjecting the polymer compound to thermal processing at a temperature in the range of 100° C. to 220° C. in presence of at least one or more excipients.

Peptides are provided herein, wherein the peptide bearing one or more amino acid sequence differences relative to SEQ ID NO: 1, with the amino acid sequence differences comprising at least one cysteine replacement.

Disclosed is a method for producing a protein fiber, the method including: bringing a spinning dope containing a protein and an organic solvent into contact with a coagulation liquid to coagulate the protein, wherein a content of the protein in the spinning dope is more than 10% by mass based on a total amount of the spinning dope, and the coagulation liquid contains water or an aqueous solution of pH 0.25 or more and pH 10.00 or less.

Disclosed are keratin fibre cellular components, specifically keratin fibre cuticle and cortical cells, and their use as absorption and filtration media, and in thermal insulation materials. The keratin fibre cellular components may be oxidised. The keratin fibre cellular components have improved absorbency and filtration capacity compared to the source keratin fibres. The keratin fibre cellular components may be used in, for example, various products for passive absorption and active filtration of gas or liquid media.

An object of the present invention is to provide a method for producing an artificial structural protein fiber having a small diameter and having a stress equal to or higher than that of the related art. A method for producing an artificial structural protein fiber according to the present invention is a method for producing an artificial structural protein fiber by a wet spinning method, the method including a coagulation step of discharging a spinning dope containing an artificial structural protein and an organic solvent from a spinneret into a coagulation liquid to coagulate the artificial structural protein, wherein a bath draft in the coagulation step is more than 0.4 and 20 or less.

The present invention provides compositions and methods for treatment, prevention or reduction of skin disease or disorders. In one embodiment, the composition comprises a peptide derived from the SD67 or SD150 region of filaggrin.

The present invention provides compositions and methods for inhibiting intermediate filament tetramerization and formation.

The present invention provides a keratin BD-6, a nucleic acid molecule encoding keratin BD-6, an expression vector containing the nucleic acid molecule, and a host cell containing the expression vector or the nucleic acid molecule integrated into genome, and preparation method of the keratin BD-6, and a pharmaceutical composition containing the keratin BD-6, and use of the above keratin BD-6, nucleic acid molecule, expression vector, host cell or pharmaceutical composition in the preparation of medicament for antipyretic, analgesic, antitussive, expectorant, anticonvulsant, antiepileptic, anti-hypertension, anti-inflammatory, and antiviral.

The present invention relates to epitopes containing homocitrulline (Hcit) that can be used as targets for cancer immunotherapy. The homocitrullinated T cell epitope has (i) a predicted binding score to MHC class II or class I of <30 using the online IEDB prediction program (http://www.iedb.org/) and (ii) at least 5 consecutive amino acids that form a spiral conformational structure. These modified peptides can be used as vaccines or as targets for T cell receptor (TCR) and adoptive T cell transfer therapies.

The present invention relates to peptides derived from known intermediate filaments which are capable of inducing cell death in metazoan cells, and/or stimulating pro-inflammatory cytokine secretion. The peptides consist of a first region of “n” amino acids, wherein “n” is 0 to 41 amino acids; a second region of 9 amino acids; wherein the sequence of 9 amino acids is [(a)/(b)]-[K/R]-[(a)/(b)]-[(a)/(b)/(c)/(d)]-[L]-[(e)]-[(a)/(b)/(c)]-[E]-[I] (SEQ ID NO: 1), wherein (a) is a nonpolar aliphatic amino acid, (b) is a polar uncharged amino acid, (c) is a positively charged amino acid, (d) is an aromatic amino acid, (e) is a negatively charged amino acid; and a third region of “m” amino acids, wherein “m” is 0 to 41 amino acids. The peptides of the invention have a minimum length of 9 amino acids and a maximum length of 50 amino acids. These peptides may be useful as new adjuvants in vaccines, either alone or in combination with other therapies; as well as chemotherapeutic agents, either alone or in combination with other drugs or therapies.